Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban

Summary Of the new direct oral anticoagulants, direct factor Xa inhibitors are limited by the absence of a proven reversal agent. We assessed the safety, tolerability and impact on anticoagulation reversal of ciraparantag (PER977) alone and following a 60 mg dose of the FXa inhibitor edoxaban. Escal...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Thrombosis and haemostasis Ročník 117; číslo 2; s. 238 - 245
Hlavní autori:	Ansell, Jack E., Bakhru, Sasha H., Laulicht, Bryan E., Steiner, Solomon S., Grosso, Michael A., Brown, Karen, Dishy, Victor, Lanz, Hans J., Mercuri, Michele F., Noveck, Robert J., Costin, James C.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Germany Schattauer GmbH 01.02.2017
Predmet:	Administration, Oral Adult Arginine - administration & dosage Arginine - adverse effects Arginine - analogs & derivatives Arginine - pharmacokinetics Blood Coagulation - drug effects Coagulation and Fibrinolysis Double-Blind Method Drug Monitoring - methods Factor Xa Inhibitors - administration & dosage Factor Xa Inhibitors - adverse effects Humans Injections, Intravenous Male North Carolina Piperazines - administration & dosage Piperazines - adverse effects Piperazines - pharmacokinetics Pyridines - administration & dosage Pyridines - adverse effects Thiazoles - administration & dosage Thiazoles - adverse effects Whole Blood Coagulation Time Ciraparantag reversal anticoagulant edoxaban whole blood clotting time
ISSN:	0340-6245, 2567-689X, 2567-689X
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!